Plain-English translation of NCT07230652 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Schizophrenia research guide →Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new medication called to see if it is safe and well-tolerated when taken by mouth over 7 days. The study includes both healthy adults and people who have been diagnosed with schizophrenia and whose symptoms are currently stable. Researchers want to understand how the medication moves through the body and whether it causes any side effects.
Schizophrenia is a serious mental health condition, and researchers are constantly looking for new treatment options that may work better or have fewer side effects than existing medications. This early-stage trial will help determine whether this new treatment is safe enough to test further in larger groups of patients.
You likely qualify if…
You likely don't qualify if…
You will visit the study site and receive either the new medication or a placebo (an inactive pill) once daily for 7 days. You cannot choose which one you receive — it is assigned randomly, and neither you nor the researchers will know which you got (double-blind). During the study, you will have blood tests, heart monitoring, eye exams, and other safety checks to make sure the medication is not causing any problems.
AI-generated summary from trial data · Jun 5, 2026 · Not medical advice
China
Phase
Safety & dosing
Sponsor
Luye Pharma Group Ltd.
Enrollment target
~40 participants
Started
August 2025
Primary completion
December 2025
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years – 60 Years
Last updated on clinicaltrials.gov in November 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Yufeng Wang
Luye Pharma Group Ltd.
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.